Arvinas has announced a platform data update that includes initial safety, tolerability, and pharmacokinetic data from the company’s ongoing Phase 1 clinical trials of ARV-110 and ARV-471. The data show dose-proportional exposures of ARV-110 and that both ARV-110 and ARV-471 have been well tolerated.
“This is the first look at clinical data from our PROTAC® platform and is an exciting milestone for both Arvinas and for the field of targeted protein degradation,” said John Houston, Ph.D., Chief Executive Officer at Arvinas. more